This communication contains forward-looking statements, including those regarding the proposed merger transaction between FHC and APP and the integration of our two businesses. These statements are subject to known and u

Proposed Merger of Aspen Park

Pharmaceuticals and The Female Health Company Transforming into A Leading Men's and Women's Health Care Company April 2016 NASDAQ: FHCO Exhibit 99.1

This communication contains

forward-looking statements, including those regarding the proposed merger transaction between FHC and APP and the integration of our two businesses. These statements are subject to known and unknown risks, uncertainties and assumptions, and if any

such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to:

the risk that the proposed transaction may not be completed in a timely manner or at all; the satisfaction of conditions to completing the transaction, including the ability to secure approval by a two-thirds vote of FHC's shareholders; risks

that the proposed transaction could disrupt current plans and operations; costs, fees and expenses related to the proposed transaction; risks related to the development of APP's product portfolio, including regulatory approvals and time and cost to

bring to market; risks relating to the ability of the combined company to obtain sufficient financing on acceptable terms when needed to fund development and company operations; the risk that, even if it is completed, we may not realize the expected

benefits from the transaction; and other risks described in FHC's filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended September 30, 2015 and our Quarterly Report on

Form 10 Q for the quarter ended December 31, 2015. These documents are available on the "SEC Filings" section of our website at http://fhcinvestor.com. All forward-looking statements are based on information available to us as

of the date hereof, and FHC does not assume any obligation and does not intend to update any forward-looking statements, except as required by law. 3_85 Forward Looking Statements

Additional Information about the

Proposed Transaction and Where You Can Find It FHC plans to file a proxy statement with the SEC relating to a solicitation of proxies from its shareholders in connection with a special meeting of shareholders of FHC to be held for the purpose of

voting on matters relating to the proposed transaction. BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTION, FHC SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME

AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The proxy statement and other relevant materials, and any other documents filed by FHC with the SEC, may be obtained free of charge at the SEC's website

at www.sec.gov. In addition, shareholders of FHC may obtain free copies of the documents filed with the SEC by contacting FHC's Chief Financial Officer at (312) 595-9123, or by writing to Chief Financial Officer, The Female Health Company, 515 North

State Street, Suite 2225, Chicago, Illinois 60654. Interests of Certain Participants in the Solicitation FHC and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders

of FHC in favor of the proposed transaction. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy

statement and other relevant materials to be filed with the SEC when they become available.

Merged company New name will be

selected to reflect new business Reincorporate FHC as a Delaware corporation Global headquarters, Miami, Florida Women's Health Division Office, Chicago FC2 compliance and international activities, London FC2 manufacturing, Malaysia Ownership

will be approximately 45% APP stockholders and 55% FHC stockholder Harry Fisch and Mitch Steiner, APP's two largest shareholders who collectively own about 85% of APP's stock, will be locked-up from selling 75% of the shares they receive in the

merger for 18 months after closing Definitive agreement signed April 5, 2016 Proxy, shareholder vote, closing expected third quarter of calendar 2016 3_85 The Proposed Merger of Aspen Park Pharmaceuticals (APP) and The Female Health Company (FHC)

Men Prostate cancer, including side

effects of treatments, >$6.4 billion1 Benign prostatic hyperplasia (BPH) >$5.2 billion2 Sexual dysfunction >$4 billion3 Premature ejaculation >$500 million4 Male infertility >$700 million5 Gout >$1.5 billion6 Women Breast cancer

>$3 billion7 Ovarian cancer >$1.5 billion8 Protection against pregnancy and sexual transmission of HIV, Zika virus and STDs 3_85 APP - FHC Merger Co. Addressing Large Global Markets MarketWatch 10/30/14 2. GlobalData 11/8/11 3.

Transparency Market Research 10/21/13 4. companiesandmarkets.com 6/30/11 5. www.alliedmarketresearch.com 6. GlobalData 4/29/2014 7. IMS 10/2/2014 8. Visiongain 7/31/2015

Combined portfolio of products and

expertise establishes the new company as a leader in men's and women's health care Complementary diversification strategy with multiple shots on goal Deep value, opportunistic, late stage development and near term products for large

markets Portfolio mostly less risky than other early-stage biopharmaceutical companies due to 505(b)(2) FDA pathway for a number of product candidates Experienced, dedicated leadership Women's Health Division: Expand existing, profitable

business; begin development of newly acquired oncology pharmaceutical products for breast and ovarian cancer Men's Health Division: Create a business unit focused on male health, especially in the areas of benign prostatic hyperplasia, male

infertility, hot flashes in men on prostate cancer therapy, gout and advanced prostate cancer; augment with the commercialization of consumer health products for premature ejaculation and sexual health vitamin supplements A financially strong

company that is unique for this stage of development in that it has revenue and earnings, no debt, and is cash flow positive A multi-product portfolio of promising potential products to provide near and future upside to shareholders 3_85 APP - FHC

Merger Co. Maximizes Both Short- and Long-Term Shareholder Value

Mitchell Steiner, MD - CEO and

President. Urologist, Aspen Park Pharmaceuticals, OPKO Health, Inc. and GTx, Inc. Harry Fisch, MD - Chief Corporate Officer. Urologist, Aspen Park Pharmaceuticals and Millennium Sciences, Inc. Daniel Haines, CPA - Chief Financial Officer.

E&Y, Equity One, Inc. (NYSE:EQY), OPKO Health (NYSE:OPK) and Lennar Corp (NYSE:LEN) Expected to join at closing: Chief Medical Officer VP Clinical Development VP of Chemistry, Manufacturing, and Controls 3_81 Experienced Management Team for

APP-FHC Merger Co. Clinical and Industry Expertise

Elgar Peerschke, MBA - Chairman.

President of Quintiles; Senior partner Global Health Care Practice of Bain and Company Mitchell Steiner, MD - Vice Chairman and CEO and President of the Company. Cofounder, CEO, President of Aspen Park Pharmaceuticals; President urology OPKO

Health (NYSE:OPK); Cofounder, CEO, and Vice Chairman of public company GTx, Inc. Board certified Urologist; and Professor and Chairman of Urology, University of Tennessee Harry Fisch, MD - Director and Chief Corporate Officer of the Company.

Cofounder and Chairman of Aspen Park Pharmaceuticals; Clinical Professor of Urology and Reproductive Medicine Cornell; Director of the Male Reproductive Center at Columbia University Medical Center; Professor of Urology Columbia University; CEO and

President of Millennium Sciences; Board certified urologist; and author O.B. Parrish - Director. Co-founder, Chairman and CEO of The Female Health Company; President of Phoenix Health Care of Illinois; Chairman of Abiant, Inc.; Director of Algasol

Renewables; President of Global Pharmaceutical Group Searle; and, Executive Vice President of Pfizer International division 3_81 Board of Directors Clinical and Industry Experience

Georges Makhoul - Director. CEO of

Constellation Holdings; President Morgan Stanley Investment Banking Europe, Middle East, and North Africa; and led National Science Foundation Research Center at Columbia University Mario Eisenberger, MD - Director. Professor of Oncology Johns

Hopkins University; head of Advanced Prostate Cancer Committee of Southwest Oncology Group; advisory boards Bristol Myers Squibb, Sanofi, Jansen, Ipsen, Medivation, Astellas, Ortho Biotech, Bayer and others; Ad Hoc member of the Oncologic Drugs

Advisory Committee of FDA; and founded Oncology Insights, Inc. (clinical trials contract research organization) Lucy Lu, MD, MBA - Director. CEO of Avenue Therapeutics; Executive VP and CFO of Fortress Biotech; Senior biotechnology equity analyst

Citigroup Investment Research; and Principal of First Albany Capital Two additional board member from FHC to be determined later 3_81 Board of Directors Clinical and Industry Experience (continued)

3_85 APP-FHC Merger Co. A

Men's and Women's Health Care Company Focused on Pharmaceutical and Consumer Health Products APP - FHC Merger Co. Women's Health Men's Health Tamsulosin DRS- BPH MSS-722- Male infertility APP-944- Hot flashes prostate

cancer APP-111- Prostate cancer APP-111/112- Gout and FMF APP-111- Breast cancer APP-111- Ovarian cancer PREBOOST Sexual health supplement FC2 Warming lube w/niacin Sexual health supplement Drugs Consumer Health Products Separate men's

and women's health divisions Drugs Consumer Health Products

Men's Health Division

Pharmaceuticals and Products Candidates in Development Benign prostate hyperplasia Tamsulosin Delayed Release Sachet (DRS) 505(b)(2) FDA pathway Bioequivalence study planned Q4 2016 and file NDA 2017 U.S. patent on proprietary formulation applied

for in 2015 Male infertility MSS-722, oral drug product candidate 505(b)(2) FDA pathway & orphan drug eligible confirmed by FDA 5/28/15 Increases GnRH, LH & FSH and restores sperm production Planned Phase 2 Q4 2016 2 issued U.S. patents with

expiration in 2021. Also seeking FDA orphan drug status exclusivity. Addition provisional application being enhanced. Hot flashes in men with prostate cancer on prostate cancer hormonal therapies APP-944, oral drug product candidate 505(b)(2) FDA

pathway PreIND meeting with FDA planned Q3 2016 PCT provisional application filed in 2015 Anti-tubulin cytotoxic therapy prostate cancer APP-111, oral tubulin targeting chemotherapy drug product candidate New chemical entity Preclinical toxicology

study 2016 Phase 1a/1b planned 2017 Licensed IP includes 3 U.S. issued patents with expiration in 2029 with possible extension to 2034. Numerous foreign issuances and applications. Gout and Familial Mediterranean Fever (MEFV mutations)

APP-111/112,oral agent that binds tubulin with wide therapeutic index New chemical entity Preclinical toxicology 2016 Phase 1 planned 2017 Licensed IP includes 3 U.S. issued patents with expiration in 2029 with possible extension to 2034. Numerous

foreign issuances and applications. 3_85

Alpha blocker benign prostatic

hyperplasia (BPH) therapeutics class generated $4.1 billion in U.S. pharmacy sales1 (in 2014) 12% is associated with long-term care facilities1 Tamsulosin (FLOMAX ) is currently the number one prescribed alpha blocker treating the

Medicare (long-term care) population1 Swallowing disorders (dysphagia) are a major problem (15% prevalence) for the elderly, especially those living in long-term care facilities2 Solution formulations are preferred in long-term care setting Poor

compliance with alpha blocker BPH drugs leads to increased risk of acute urinary retention, urosepsis and death APP's Tamsulosin DRS is a novel oral formulation for men with BPH and swallowing difficulties. 3_85 Benign Prostate Hyperplasia,

Well-Established Market Alpha Blockers Most Commonly Prescribed Drug Class 1 Source: IMS Health Data March 2015 2 Source: Clinical Interventions in Aging 2013:8 221-227

BPH Alpha Blocker Sales Tamsulosin

(FLOMAX ) Has ~85% Market Share ATC4 MAT Mar 2015 TRx MAT Mar 2015 TRx Market Share MAT Mar 2015 TRx Pharmacy $ MAT Mar 2015 TRx Pharmacy $ Market Share MAT Mar 2015 EUTRx $/Unit G04C2 BPH A-ADRENERG ANTAG PLN 29,233,610 100.00% $4,142,576,343

100.00% 1,478,295,890 2.80 TAMSULOSIN 23,317,951 79.76% $3,475,988,912 84.84% 1,150,429,482 3.02 COMBINED RETAIL 18,399,025 78.90% $2,606,030,239 88.56% 883,435,533 2.95 LONG-TERM CARE 3,131,953 13.43% $336,594,324 11.44% 86,185,219 3.91 MAIL

SERVICE 1,759,171 7.54% $ 527,632,160 0.00% 178,865,537 2.95 SPECIALTY MAIL SERVICE 27,802 0.12% $ 5,732,189 0.00% 1,943,193 2.95 TERAZOSIN 3,747,430 12.82% $224,324,678 5.45% 225,105,689 1.00 COMBINED RETAIL 3,014,920 80.45% $173,334,504 91.73%

178,021,751 0.97 LONG-TERM CARE 377,636 10.08% $15,621,210 8.27% 10,758,540 1.45 MAIL SERVICE 348,340 9.30% $ 34,867,700 0.00% 35,810,579 0.97 SPECIALTY MAIL SERVICE 6,534 0.17% $ 501,264 0.00% 514,819 0.97 SILODOSIN 960,001 3.28% $243,925,303 5.53%

41,088,243 5.94 COMBINED RETAIL 797,089 83.03% $183,758,517 95.87% 30,994,595 5.93 LONG-TERM CARE 63,001 6.56% $7,921,218 4.13% 1,281,375 6.18 MAIL SERVICE 99,645 10.38% $ 52,160,242 0.00% 8,797,881 5.93 SPECIALTY MAIL SERVICE 266 0.03% $ 85,326

0.00% 14,392 5.93 ALFUZOSIN 1,208,228 4.13% $198,337,450 4.18% 61,672,476 3.22 COMBINED RETAIL 974,681 80.67% $140,176,755 96.58% 43,813,168 3.20 LONG-TERM CARE 48,917 4.05% $4,960,066 3.42% 1,231,101 4.03 MAIL SERVICE 182,833 15.13% $ 52,741,746

0.00% 16,484,780 3.20 SPECIALTY MAIL SERVICE 1,797 0.15% $ 458,883 0.00% 143,427 3.20 Source: IMS Health Data March 2015

Initiate a focused contracting

strategy (rebate/performance based) with specialty GPOs to provide immediate access to long term care population 12% of market in long term care facilities 2 Labs, Inc. has expertise in contracting with all third party logistics and providers

Tamsulosin DRS can be differentiated in pharmaceutical compendium Priced at 70% of branded tamsulosin (FLOMAX ) tablet, tamsulosin DRS could capture ~5% of the total alpha blocker BPH market in US: Tamsulosin DRS ~$300 million annually Grow

revenue by pharmacy switch and by expanding reach into geriatric PCPs & urologists 15% of elderly patients who are not in long-term care suffer from dysphagia and could provide upside1 Build awareness of a new formulation of gold standard

product among geriatric and urology health care providers 3_85 Tamsulosin DRS No Sales Force Needed 1.Sura L et al. Clinical Interventions in Aging 7:287-298 2012

Drug API/ Product Tamsulosin DRS

Anticipated Clinical Development Plan 505(b)(2) Indication: BPH 2015 2016 2017 BE study 140294_84 3_84 4_84 48_84 65_84 70_84 2Q 1Q 3Q 4Q 2Q 1Q 3Q 4Q 2Q 1Q 3Q 4Q PreIND Meeting 505(b)(2) File NDA 2018 2Q 1Q 3Q 4Q PreNDA Meeting 505(b)(2)

Male Infertility A Growing and

Underserved Market Infertility affects 6.1 million couples in US, which is 15% of all couples trying to conceive1 50% of infertility is attributed to males who present with abnormal semen analysis1,2 2% of infertile men have adult onset form of

idiopathic hypogonadotropic hypogonadism (abnormal hypothalamic-pituitary-gonadal axis) 1-4 hCG injection (LH-like activity) and FSH injections are only FDA approved therapies4,5 Clomiphene (racemic mixture) is used as first line empirical therapy

in 90% of idiopathic infertile men6 Off-label use Most effective and safe dose as well as schedule are not known No FDA approved oral therapies5 APP's MSS-722 is being developed as the first oral agent for the treatment of idiopathic male

infertility 3_85 1.Roth LW et al. Semin Reprod Med 31:245-250 2013; 2.Chehab M et al Fertil Steril 103:595-604 2015; 3.Whitten SJ etal Fertil Steril 86:1664-1668 2006; 4. Nachtigall LB et al. N Engl J Med 336:410-415 1997. 5.

https://rarediseases.info.nih.gov/gard/diseases-with-medical-products/H 6.Ko EY et al J Urol 187:973-978 2012

18_85 11_84 MSS-722 Male Infertility

Efficacy Data from Literature Efficacy Chua M et al Andrology 1:749-757 2013.

18_85 11_84 MSS-722 Clomiphene

Safety in Men & Women Carmargo Pharmaceutical Services Feasibility and Clinical Report 3/3/15 39 published studies in men taking clomiphene 2220 men, duration from 8 weeks to 3 years, and doses from 25mg-200mg/day Reported adverse events

included visual symptoms (blurring, spots, and flashes), gynecomastia, nipple tenderness, hot flashes, increased facial hair, increased facial acne, increased testicular volume, increased body weight, melena, dizziness, and headache"

FDA confirmed that MSS-722 qualifies

for 505(b)(2) pathway Utilize a fixed proprietary ratio of cis and trans isomers Indication of idiopathic male infertility with hypogonadotropic hypogonadism not due to primary testicular failure would be acceptable* Population - men with

hypogonadotropic hypogonadism (low testosterone levels) and infertility (low sperm counts) Acute therapy (5 months = 2 cycles) No carcinogenicity studies or additional animal studies would be required in this setting Primary endpoint that would

represent clinical benefit may be the proportion of men who become fertile (improvement in sperm count into fertile range) Orphan drug request sent to FDA January 7th 2016 18_85 11_84 MSS-722 Treatment of Male Infertility- FDA Meeting May 28th 2015

* Rare Diseases with FDA approved products- https://rarediseases.info.nih.gov/gard/diseases-with-medical-products/H

Drug API/ Product MSS-722 Clinical

Development Plan 505(b)(2) Indication: Infertility in Men with Hypogonadism 2015 2016 2017 Phase 2 Dose finding Interim analysis 2.5 months Final 5 months 120 patients 140294_84 3_84 4_84 48_84 65_84 70_84 2Q 1Q 3Q 4Q 2Q 1Q 3Q 4Q 2Q 1Q 3Q 4Q Phase 3

X 2 8 months PreIND Meeting 505(b)(2) File IND File NDA 2018 2Q 1Q 3Q 4Q